



## Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference

September 9, 2024

DOYLESTOWN, Pa., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) ("Aprea" or the "Company"), a clinical stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced that Oren Gilad Ph.D, President and Chief Executive Officer, will deliver an in-person presentation at the H.C. Wainwright 26<sup>th</sup> Annual Global Investment Conference, taking place September 9-11, 2024 in New York, NY. Details are as follows:

### H.C. Wainwright 26<sup>th</sup> Annual Global Investment Conference

Date: September 10, 2024  
Time: 9am ET  
Location: Holmes II, Lotte New York Palace Hotel  
Webcast: click [here](#)

The webcast will also be archived on Aprea's corporate website.

Management are also available for one-on-one meetings with institutional investors. To request a meeting, please contact your conference representative.

### **About Aprea**

Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Doylestown, Pennsylvania, focused on precision oncology through synthetic lethality. The Company's lead program is ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small molecule WEE1 inhibitor, recently entered the clinic. For more information, please visit the company website at [www.aprea.com](http://www.aprea.com).

The Company may use, and intends to use, its investor relations website at <https://ir.aprea.com/> as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD.

### **Investor Contact:**

Mike Moyer  
LifeSci Advisors  
[mmoyer@lifesciadvisors.com](mailto:mmoyer@lifesciadvisors.com)

### **Media Contacts:**

Ignacio Guerrero-Ros, Ph.D., or David Schull  
Russo Partners, LLC  
[ignacio.guerrero-ros@russopartnersllc.com](mailto:ignacio.guerrero-ros@russopartnersllc.com)  
[David.schull@russopartnersllc.com](mailto:David.schull@russopartnersllc.com)  
(858) 717-2310